country (5). These cases might be secondary to exposure to the 9-banded armadillo (Dasypus novemcinctus), which lives in the area (2). Most HD patients in Louisiana, Texas, and Florida who had not traveled outside the United States were infected with the *M. leprae* strain 3I-2-v1, which is found in most infected armadillos (2). Although direct contact with armadillo blood or flesh poses the highest risk, HD has been reported in persons without direct exposure (8). These patients might have had exposure to contaminated soil (9). Alternatively, other environmental reservoirs might be responsible, exemplified by the discovery of infected Eurasian red squirrels (*Sciurus vulgaris*) in the British Isles (10).

*M. leprae* genomic analysis strongly suggests that our patient acquired the infection with the armadillo-associated *M. leprae* strain during a trip to Florida. This case highlights the possibility of HD being acquired within North America without obvious exposure to known animal reservoirs. Travelers to the southern United States should be advised to avoid contact with armadillos.

Acknowledgments

We thank the staff at National Hansen’s Disease Program, Baton Rouge, Louisiana, USA, for performing bacteriologic index analyses and genotyping.

About the Author

Dr. Bonnar, an infectious diseases graduate, completed a clinical fellowship in antimicrobial stewardship at the University of Toronto in Toronto, Ontario, Canada. His primary research interests include quality improvement projects to optimize antimicrobial use.

References

1. Truman RW, Andrews PK, Robbins NY, Adams LB, Krahenbuhl JL, Gillis TP. Enumeration of *Mycobacterium leprae* using real-time PCR. PLoS Negl Trop Dis. 2008;2:e328. http://dx.doi.org/10.1371/journal.pntd.0000328
2. Truman RW, Singh P, Sharma R, Busso P, Rougemont J, Paniz-Mondolfi A, et al. Probable zoonotic leprosy in the southern United States. N Engl J Med. 2011;364:1626–33. http://dx.doi.org/10.1056/NEJMoa1010536
3. Sharma R, Singh P, Loughry WJ, Lockhart JM, Inman WB, Duthie MS, et al. Zoonotic leprosy in the southeastern United States. Emerg Infect Dis. 2015;21:2127–34. http://dx.doi.org/10.3201/eid2112.150501
4. Public Health Agency of Canada. Reported cases from 1924 to 2014 in Canada—notifiable diseases on-line. 2016 June 28 [cited 2016 Nov 21]. http://diseases.canada.ca/notifiable/charts?c=plt
5. US Department of Health and Human Services Health Resources and Services Administration National Hansen’s Disease Program. Highlights from a summary of Hansen’s disease (leprosy) in the United States 2015. 2016 [cited 2016 Nov 21]. http://www.hrsa.gov/hansendisease/dataandstatistics.html
6. Boggild AK, Correia JD, Keystone JS, Kain KC. Leprosy in Toronto: an analysis of 184 imported cases. CMAJ. 2004;170:55–9.
7. Truman R, Fine PE. ‘Environmental’ sources of *Mycobacterium leprae*: issues and evidence. Lepr Rev. 2010;81:89–95.
8. Marcos LA, Conerly S, Walker S. Leprosy. Am J Trop Med Hyg. 2014;91:216. http://dx.doi.org/10.4269/ajtmh.13-0668
9. Lavania M, Katao K, Katao VM, Gupta AK, Chauhan DS, Sharma R, et al. Detection of viable *Mycobacterium leprae* in soil samples: insights into possible sources of transmission of leprosy. Infect Genet Evol. 2008;8:627–31. http://dx.doi.org/10.1016/j.meegid.2008.05.007
10. Avanzi C, Del-Pozo J, Benjak A, Stevenson K, Simpson VR, Busso P, et al. Red squirrels in the British Isles are infected with leprosy bacilli. Science. 2016;354:744–7. http://dx.doi.org/10.1126/science.aah3783

Address for correspondence: Paul E. Bonnar, Dalhousie University, Infectious Diseases, 5072, 5th Fl Dickson Bldg, 5780 University Ave, Halifax, NS B3H 1V7, Canada; email: paule.bonnar@nshealth.ca

**Emmonsia helica Infection in HIV-Infected Man, California, USA**

Martin Rofael, Ilan S. Schwartz, Lynne Sigler, Li K. Kong, Nicholas Nelson

Author affiliations: Highland Hospital, Oakland, California, USA (M. Rofael, L.K. Kong, N. Nelson); University of Manitoba, Winnipeg, Manitoba, Canada (I.S. Schwartz); University of Texas Health San Antonio, San Antonio, Texas, USA (I.S. Schwartz); University of Alberta, Edmonton, Alberta, Canada (L. Sigler)

DOI: https://doi.org/10.3201/eid2401.170558

Emmonsia-like fungi have rarely been reported from North America. We report a fatal case of *E. helica* infection in a man with advanced HIV infection from California, USA, who had progressive respiratory failure and a brain abscess.

In January 2016, a 40-year-old man sought care at a hospital in Alameda County, California, USA, with a 2-week history of progressive cough, dyspnea, pleuritic chest pain, and headache associated with fevers, chills, and night sweats. He had lost 45 kg during the past month. He had a history of inconsistently treated HIV infection and a 10-pack-per-year smoking history. He had emigrated from Mexico 10 years earlier, lived in the East Bay, and had traveled to the Central Valley of California.

10-pack-per-year smoking history. He had emigrated from Mexico 10 years earlier, lived in the East Bay, and had traveled to the Central Valley of California.
On examination, he was cachectic, afebrile, hypoxic, and tachypneic. He had oral thrush, bilateral lower lobe crackles, and decreased breath sounds. The rest of the examination, including neurologic and skin assessments, was unremarkable.

Chest radiograph and computerized tomographic scan showed diffuse micronodularities with cavitory lesions in both lungs (Figure, panels A, B). Magnetic resonance imaging of the brain revealed a 6-mm ring-enhancing cerebellar lesion (Figure, panel C).

Laboratory results revealed a CD4 count and viral load of 5 cells/µL and 15,000 copies/mL, respectively. Blood leukocyte count was 14.9 × 10⁹ cells/µL (reference 4.5–11 × 10⁹ cells/µL), and hemoglobin was 11 g/dL (reference 13.5–17.5 g/dL). Lactate dehydrogenase, alkaline phosphatase, and γ-glutamyl transferase were 284 units/L (reference 125–243 U/L), 148 units/L (reference 38–126 U/L), and 242 units/L (reference 3–95 U/L), respectively. Cerebrospinal fluid analyses, including cell count, protein, and glucose measurements, showed standard results.

Molecular testing of bronchoalveolar lavage (BAL) fluid for respiratory viruses showed negative results. Serologic test results for blood and urine for coccidioidomycosis, cryptococcosis, toxoplasmosis, and tuberculosis were negative, but the Histoplasma galactomannan urine antigen test (MiraVista, Indianapolis, IN, USA) result was positive at >25 ng/mL (reference <0.5 ng/mL). Examination of cerebrospinal fluid with Gram, acid-fast, and India ink stains and aerobic, mycobacterial, and fungal cultures were negative for organisms. Cytopathologic examination of BAL fluid and lung biopsy samples showed nonnecrotizing granulomas with hematoxylin and eosin stain and both hyphal and yeast forms with fungal stains. The yeasts exhibited multiple budding with broad bases (Figure, panel D). No organisms were seen with an acid-fast stain. Multiple sputum cultures were negative for mycobacteria.

Empiric treatment was initiated for coccidioidomycosis, Pneumocystis jirovecii pneumonia, tuberculosis, and bacterial sepsis with intravenous fluconazole; trimethoprim-sulfamethoxazole with steroids; rifampin, isoniazid, pyrazinamide, and ethambutol; and broad-spectrum antimicrobial drugs. On hospital day 2, the patient had hypoxic respiratory arrest and was intubated. Antifungal drugs were changed to micafungin on day 3 and then to liposomal amphotericin B (5 mg/kg/day) on day 6, and he was extubated later that day. Tuberculosis therapy was discontinued on day 15. Antiretroviral therapy was held because of concern that immune reconstitution might worsen the patient’s cerebellar lesion. A spontaneous pneumothorax and respiratory failure developed that required reintubation on day 31. His family chose comfort care, and antifungal therapy was stopped on day 41. He died on day 43; autopsy was declined.

We sent a mold grown from BAL to a mycology reference laboratory for identification. On microscopic examination of the mold phase, conidia were absent in all subcultures. DNA sequences of the D1/D2 region of the large subunit and internal transcribed spacer region of the ribosomal RNA gene were compared with GenBank nBLAST database (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch); sequence similarities of 100% and 99%, respectively, were demonstrated for Emmonsia helica strains (including UAMH 3398, UAMH 10539, and UAMH 10593; UAMH Centre for Global Microfungal Biodiversity, University of Toronto, Toronto, Ontario, Canada).

We conducted antifungal susceptibility testing of the mold phase. MICs (µg/mL) to fluconazole, itraconazole, posaconazole, voriconazole, and amphotericin B were 8, 0.125, 0.125, <0.03, and 0.06, respectively.

Emmonsia-like fungi are an emerging group of pathogens reported globally, which predominantly cause disseminated disease of immunocompromised persons (1). One of these, E. helica, was originally recorded from North America (2). The first reported case occurred in Alberta, Canada, in 1970 in a farmer with a fatal pneumonia and encephalitis syndrome (3). A fungal pathogen isolated postmortem from brain and lung tissue was initially identified as Blastomyces dermatitidis on the basis of serologic and histopathologic findings, but

**Figure.** Emmonsia helica infection in an immunocompromised man, California, USA, 2016. A) Chest radiograph with diffuse micronodularities throughout both lung fields. B) Computed tomographic scan with diffuse micronodular pulmonary disease. C) Axial magnetic resonance image with 6-mm ring-enhancing lesion in the right cerebellum adjacent to the fourth ventricle. D) Grocott's methenamine-silver stain showing broad-based budding yeast. Original magnification ×400.
its features in culture were atypical (3). In 2015, Sigler determined that this isolate belonged to a new *Emmonsia*-like species, which she described as *E. helica* (3). Another fatal case of *Emmonsia* infection was reported from California in a patient after an orthotopic liver transplant (4). An isolate from that patient also was confirmed as *E. helica* (I. Schwartz et al., unpub. data).

Although the travel history for the second case-patient was not reported (4) and the patient in this report had resided in Mexico, these cases suggest that the area of endemicity of *E. helica* may include California. This finding is further supported by 2 other fatal cases of atypical mycoses reported in HIV-infected men from California (5); histopathologic findings of hyphae and multiple budding yeasts were consistent with *E. helica* (I. Schwartz et al., unpub. data). Investigations are under way to characterize the geographic and host range of *E. helica* and to clarify the phylogenetic relationships among members of the family *Ajellomycetaceae* comprising the genera *Emmonsia*, *Blastomyces*, *Histoplasma* and others because recent studies have uncovered far greater complexity than previously supposed (1,6).

Acknowledgments
We thank Valerie Ng, Nancy Li, Ken Schneider, Louise Troung, and Sudharshan Parthasarathy for the radiographic and histopathologic images used in the Figure. We also thank James Scott for his assistance with the case.

About the Author
Dr. Rofael is a third-year internal medicine resident at Alameda County Medical Center in Oakland, California. His research interests include pulmonary medicine, critical care, infectious diseases, and global medicine in resource-poor settings.

References
1. Schwartz IS, Kenyon C, Feng P, Govender NP, Dukik K, Sigler L, et al. 50 Years of *Emmonsia* disease in humans: the dramatic emergence of a cluster of novel fungal pathogen. PLoS Pathog. 2015;11:e1005198. http://dx.doi.org/10.1371/journal.ppat.1005198
2. Sigler L. *Emmonsia helica* Sigler sp. nov. Index Fungorum 2015: 237 [cited 2017 Oct 26]. http://www.indexfungorum.org/Publications/Index%20Fungorum%20no.237.pdf
3. Sekhon AS, Jackson FL, Jacobs HJ. Blastomycosis: report of the first case from Alberta, Canada. Mycopathologia. 1982;79:65–9. http://dx.doi.org/10.1007/BF00468081
4. Kappagoda S, Adams JY, Luo R, Banaei N, Concepcion W, Ho DY. Fatal *Emmonsia* sp. infection and fungemia after orthotopic liver transplantation. Emerg Infect Dis. 2017;23:346–9. http://dx.doi.org/10.3201/160799
5. Tan G, Kaufman L, Peterson EM, de la Maza LM. Disseminated atypical blastomycosis in two patients with AIDS. Clin Infect Dis. 1993;16:107–11. http://dx.doi.org/10.1093/chidress/16.1.107
6. Dukik K, Muñoz JF, Jiang Y, Feng P, Sigler L, Stielow JB, et al. Novel taxa of thermally dimorphic systemic pathogens in the *Ajellomyctaceae* (Onygenales). Mycoses. 2017;60:296–309. http://dx.doi.org/10.1111/myc.12601

Address for correspondence: Martin Rofael, Alameda County Medical Center—Internal Medicine, 1411 E 31st St., A2 QIC 22130, Oakland, CA, 94602-1018 USA; email: mrofael@gmail.com

Costs of Conjunctivitis Outbreak, Réunion Island, France

Laurent Filleul, Frederic Pagès, Guy-Noel Chan Wan, Elise Brottet, Pascal Vilain

Author affiliations: Santé Publique France, French National Public Health Agency, Saint-Denis, Réunion, France (L. Filleul, F. Pagès, E. Brottet, P. Vilain); Agence Régionale de Santé Océan Indien, Regional Public Health Authority, Saint-Denis (G.-N.C. Wan)

DOI: https://doi.org/10.3201/eid2401.170916

During January–April 2015, a major outbreak of conjunctivitis on Réunion Island caused a large public health impact. On the basis of general practitioner consultations, emergency department visits, and eye medication sales during the 13-week epidemic, we estimated a total healthcare cost of €3,341,191 from the outbreak.

During January–April 2015, a major outbreak of acute hemorrhagic conjunctivitis occurred on Réunion Island, causing a heavy impact on the national healthcare system of France (I). Réunion Island, a French overseas administrated territory, is located in the Indian Ocean between Madagascar and Mauritius; it has a surface area of 2,512 km² and a population of ≈840,000 (1.3% of France’s population, including the nation’s overseas territories; https://www.insee.fr/fr/statistiques/2119468).

The island is included in the national health insurance (NHI) program of France. Réunion Island’s health system is similar to that of France; however, most patients on the island do not pay provider health fees directly. NHI pays the general practitioner (GP), the pharmacist, or hospital. Rarely, the patients pay for the GP consultations and emergency department (ED) visits, but these costs will be refunded to the patients by the NHI. Healthcare costs are higher (≈30%) on the island than in mainland France. In 2015, total healthcare expenditures in Réunion Island were